Technology enabling thermally-controlled DNA synthesis
pharmafile | April 5, 2022 | News story | Manufacturing and Production |
Evonetix has been granted a patent in Europe for thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips. This patent, EP3551331B1, is a key step in the company’s strategy to develop a benchtop DNA synthesis platform, to change how DNA is accessed, made, and used.
The company’s novel approach to parallel DNA synthesis is underpinned by precise and independent control of temperature at thousands of individual synthesis sites across the surface of a silicon chip.
In contrast to conventional approaches, which use acid deprotection to control the synthesis cycle, Evonetix uses thermal control, with semiconductor-based arrays. This offers greater accuracy and selectivity to deprotect sequences at the correct point to add the next nucleotide, and remove mismatching sequences.
Matthew Hayes, Chief Technology Officer at Evonetix, commented: “There is currently an unmet need in the synthetic biology industry for long, accurate, DNA sequences, and the ability to remove errors during assembly allows researchers to achieve longer strands of DNA, and run applications such as gene synthesis, CRISPR screening, and protein engineering. Securing this patent to cover our core technology adds further strength to our IP portfolio and underlines Evonetix’s position as leaders in our field.
“Our technology will give researchers the capabilities of service centres in their own lab, accelerating the advancement of synthetic biology and opening new possibilities in this exciting market.”
Evonetix is a synthetic biology company, aiming to reimagine biology by developing a radically different approach to gene synthesis through a highly parallel desktop platform, synthesising DNA at an unprecedented accuracy and scale.
This platform will place DNA synthesis in the hands of every researcher, and change how DNA is utilised. The new paradigm in gene synthesis will facilitate and enable the rapidly growing field of synthetic biology.